Valuation conundrum of healthcare-related stocks in US and M’sia


THE United States, which is the epicentre of the Covid-19 pandemic, is the base for some of the world’s largest healthcare companies. These companies are in the race to find a vaccine for the virus and have from time to time disclosed the progress of finding a wonder drug to prevent the spread of the virus.

However, the valuations of the more established pharmaceutical companies have remained sober even though the companies are in the forefront of the search to find a vaccine.

The Star Festive Promo: Get 35% OFF Digital Access

Monthly Plan

RM 13.90/month

Best Value

Annual Plan

RM 12.33/month

RM 8.02/month

Billed as RM 96.20 for the 1st year, RM 148 thereafter.

Follow us on our official WhatsApp channel for breaking news alerts and key updates!

Next In Business News

Ringgit closes higher against greenback on cautious market sentiment
T7 Global subsidiary appointed panel contractor for PETRONAS
YTL inks RM200mil naming rights deal with Aviva for Bristol arena
KL High Court dismisses appeals of former Jalatama officers
Well Chip posts FY25 net profit jump to RM86.15mil
Angkasa targets 2026 revenue to reach up to RM75bil
Aeon Credit issues RM100mil five-year senior sukuk
Late bargain-hunting lifts Bursa Malaysia to end higher
Net foreign inflows into Malaysian bonds reach RM951.9mil in January - RAM Ratings
Wawasan Dengkil's 2Q net profit falls due to revision of project costs

Others Also Read